Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/febs.15784 http://scihub22266oqcxt.onion/10.1111/febs.15784 33621437!8013755!33621437     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       FEBS+J 2021 ; 288 (17): 5179-5189 Nephropedia Template TP {{tp|p=33621437|t=2021. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection |pdf=|usr=}}{{33621437}} gab.com Text The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection JO: FEBS J http://www.kidney.de/pget.php?&tw=1&pmid=33621437 #FOAvip Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID-19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID-19 susceptibility and disease duration. We conducted a retrospective population-based cross-sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID-19-positive group, as compared to the COVID-19-negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID-19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 +/- 12.79 vs. 56.63 +/- 12.28 years of age; P < 0.001), presented a lower BMI (28.77 +/- 5.4 vs. 30.37 +/- 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID-19 disease duration (considered as the time between the first positive and second negative COVID-19 RT-PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 +/- 7.8 vs. 21.9 +/- 7.9 P = 0.045). Among hospitalized COVID-positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID-19 infection, disease duration and mortality, and aspirin use for primary prevention. Twit Text FOAVip The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection ????FEBS J http://www.kidney.de/pget.php?&tw=1&pmid=33621437 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33621437 #FOAvip English Wikipedia <ref>{{Cite pmid|33621437}}</ref> The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection #MMPMID33621437 Merzon E; Green I; Vinker S; Golan-Cohen A; Gorohovski A; Avramovich E; Frenkel-Morgenstern M; Magen E FEBS J 2021[Sep]; 288 (17): 5179-5189 PMID33621437show ga Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID-19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID-19 susceptibility and disease duration. We conducted a retrospective population-based cross-sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID-19-positive group, as compared to the COVID-19-negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID-19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06 +/- 12.79 vs. 56.63 +/- 12.28 years of age; P < 0.001), presented a lower BMI (28.77 +/- 5.4 vs. 30.37 +/- 4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID-19 disease duration (considered as the time between the first positive and second negative COVID-19 RT-PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8 +/- 7.8 vs. 21.9 +/- 7.9 P = 0.045). Among hospitalized COVID-positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID-19 infection, disease duration and mortality, and aspirin use for primary prevention. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Aged[MESH] |Aspirin/*administration & dosage/adverse effects[MESH] |COVID-19/complications/virology[MESH] |Cardiovascular Diseases/complications/*drug therapy/virology[MESH] |Diabetes Mellitus/drug therapy/virology[MESH] |Humans[MESH] |Hypertension/complications/drug therapy/virology[MESH] |Male[MESH] |Middle Aged[MESH] |Primary Prevention[MESH] |Retrospective Studies[MESH] |Risk Factors[MESH]The use of aspirin for primary prevention of cardiovascular disease is(epmc).pdf DeepDyve Pubget Overpricing